Shots:

• The designation is based on an ongoing P-II (LUMINOSITY/ M14-239) study evaluating Teliso-V monothx. in patients with advanced/m-EGFR WT, nonsq. NSCLC with high levels of c-Met overexpression whose disease has progressed on or after Pt-based therapy
• The 1EPs of the study is ORR per central review in patients with ≥ 12wks. follow-up. in patients with EGFR WT nonsq. NSCLC, ORR (53.8% & 25.0%) in c-Met high & intermediate group respectively at a previously reported interim analysis
• Teliso-V is being evaluated in the ongoing P-I (M14-237) study in combination with osimertinib for NSCLC. The therapy is also evaluated as monothx. in the P-III (TeliMET NSCLC-01/ M18-868) for the same indication

Ref: AbbVie | Image: Investopedia